BRCA1 and ovarian carcinoma: Furthermore, the PARP inhibitors' extraordinary activity in cellular systems lacking HR repair has been demonstrated in preclinical investigations by a synthetic lethality rationale, and this activity has been confirmed in clinical trials in BRCA1/2 mutation carriers with ovarian carcinomas [7].